#1 Clinical Trials Search in Europe

Molidustat Sodium

Molidustat Sodium, a novel drug, is currently being studied in clinical trials for the treatment of certain blood cancers. This article explores its potential use in patients with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have relapsed or are resistant to previous treatments. The ongoing research aims to determine the effectiveness and safety of combining Molidustat with another drug called ivosidenib in these difficult-to-treat cases.

Table of Contents

What is Molidustat?

Molidustat sodium, also known by its brand name MUSREDO, is an investigational drug being studied for the treatment of certain blood disorders[1]. It belongs to a class of medications called PHD (prolyl hydroxylase domain) inhibitors, which work by affecting the body’s oxygen-sensing mechanisms[1].

Target Conditions

The clinical trial is focusing on two main conditions:

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow and blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells.

Specifically, the study targets adult patients with relapsed or refractory (difficult to treat) AML or MDS/AML that have a specific genetic mutation called IDH1[1]. These patients are typically not eligible for intensive chemotherapy or stem cell transplantation.

How It Works

Molidustat is being studied in combination with another drug called ivosidenib, which is an IDH1 inhibitor. The combination is thought to work in the following ways:

  1. Molidustat, as a PHD inhibitor, may help increase the production of red blood cells by mimicking the body’s response to low oxygen levels.
  2. Ivosidenib targets the mutated IDH1 enzyme, which is present in some leukemia cells.

Together, these medications aim to inhibit the growth of leukemia cells and potentially improve blood cell production[1].

Clinical Trial Overview

The clinical trial, known as MOLIVO-1/AMLSG33-22, is a Phase Ia/IIb study designed to investigate the effectiveness and safety of molidustat in combination with ivosidenib[1]. The study has two main parts:

  • Phase Ia: This part aims to determine the recommended dose of molidustat for further study.
  • Phase IIb: This part will assess the initial effectiveness of the combination treatment by measuring the complete remission rate.

Potential Benefits

The study aims to evaluate several potential benefits for patients, including:

  • Achieving complete remission or partial remission of the disease
  • Becoming independent from blood transfusions
  • Improved survival rates
  • Reduction in minimal residual disease (small numbers of cancer cells that remain after treatment)

Safety and Side Effects

As with any investigational treatment, safety is a primary concern. The study will closely monitor patients for side effects and adverse events. Some potential areas of concern include:

  • Effects on heart function and heart rhythm
  • Liver function
  • Interactions with other medications
  • General side effects such as nausea, fatigue, or changes in blood cell counts

Patients will be regularly assessed for any signs of toxicity or adverse reactions[1].

Administration

Molidustat is administered orally in tablet form[1]. The exact dosing schedule will be determined during the Phase Ia portion of the study. Patients will need to be able to swallow and retain oral medication to participate in the trial.

Conclusion

Molidustat sodium represents a promising new approach to treating certain types of blood cancers, particularly for patients who have limited treatment options. While the results of this clinical trial are not yet known, it offers hope for improved outcomes in patients with IDH1-mutated AML or MDS/AML. As with any experimental treatment, it’s important for patients to discuss the potential risks and benefits with their healthcare providers and to understand that further research is needed to establish the drug’s effectiveness and safety profile.

Aspect Details
Drug Name Molidustat Sodium (MUSREDO)
Trial Phase Phase Ia/IIb
Target Conditions IDH1-mutated relapsed/refractory AML or MDS/AML
Combination Therapy Molidustat + Ivosidenib
Primary Objectives Determine safe dosage, assess complete remission rate
Key Eligibility Adult patients, IDH1 mutation, not eligible for intensive chemotherapy
Main Endpoints Complete remission rate, survival outcomes, minimal residual disease status
Safety Monitoring Adverse events, organ function, QT interval prolongation

FAQ

  • What is Molidustat Sodium and how does it work? Molidustat Sodium is a PHD inhibitor, which means it affects the body's oxygen-sensing mechanisms. In this trial, it's being studied in combination with ivosidenib, an IDH1 inhibitor, to target specific genetic mutations in blood cancer cells.
  • What types of blood cancers are being studied with Molidustat Sodium? The clinical trial is focusing on adult patients with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has relapsed or become resistant to previous treatments.
  • Who is eligible for this clinical trial? Eligible patients are adults with relapsed or refractory IDH1-mutated AML or MDS/AML who are not suitable for intensive chemotherapy or stem cell transplantation. They must meet specific criteria regarding organ function and previous treatments.
  • What are the main goals of this clinical trial? The trial aims to determine the safe dosage of Molidustat and assess its effectiveness when combined with ivosidenib. Researchers will measure complete remission rates, survival outcomes, and minimal residual disease status.
  • What are some potential side effects being monitored in this trial? The trial is closely monitoring for any adverse events, with special attention to heart-related issues, liver function, and changes in blood counts. Patients are also being checked for potential drug interactions and QT interval prolongation.

Ongoing Clinical Trials on Molidustat Sodium

Unfortunately, we did not find any clinical trials matching the selected criteria. Try changing the filter settings or broadening the search criteria to see more available research participation opportunities.

Glossary

  • Acute Myeloid Leukemia (AML): A type of blood cancer that affects the bone marrow and blood, characterized by rapid growth of abnormal white blood cells.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells, sometimes progressing to AML.
  • IDH1 Mutation: A genetic change in the IDH1 gene, which is found in some cases of AML and MDS, and can be targeted by specific treatments.
  • Relapsed/Refractory: Refers to cancer that has returned after treatment (relapsed) or is not responding to treatment (refractory).
  • Complete Remission (CR): A treatment outcome where there are no detectable cancer cells and blood counts have returned to normal levels.
  • Minimal Residual Disease (MRD): The small number of cancer cells that may remain after treatment, often undetectable by standard tests.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and biochemical effects.
  • QT Interval: A measurement on an electrocardiogram that represents the time for electrical activity in the heart's ventricles.
  • Allogeneic Hematopoietic Cell Transplantation (alloHCT): A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor.

References

  1. http://clinicaltrials.eu/trial/study-on-molidustat-and-ivosidenib-for-adults-with-relapsed-or-refractory-idh1-mutated-acute-myeloid-leukemia-or-myelodysplastic-syndrome/